PCT/GB99/04311

09/869079

The Patent Office

INVESTOR IN PEOPLE

GB99/4311

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN COMPLIANCE WITH RULE 17.1(a) OR (b)

Signed

Dated 12 April 2000

Patents Form 1/77

Patents Act 1977
(Rule 16)

The Patent Office

22 DEC 1998 1/77

2305098 E414032-1 D02882
P01/7700 0.00 - 9828375.7

THE PATENT OFFICE
A
22 DEC 1998
LONDON

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

1.	Your reference	**SCB/51869/000**
2.	Patent application number *(The Patent Office will fill in this part)*	**9828375.7**
3.	Full name, address and postcode of the or of each applicant *(underline all surnames)*	**JANSSEN PHARMACEUTICA N.V.** **TURNHOUTSEWEG 30** **B-2340 BEERSE** **BELGIUM**
	Patents ADP number *(if you know it)*	S31939001
	If the applicant is a corporate body, give the country/state of its incorporation	**BELGIUM**
4.	Title of the invention	**HUMAN AKT-3**
5.	Name of your agent *(if you have one)* "Address for service" in the United Kingdom to which all correspondence should be sent *(including the postcode)*	**BOULT WADE TENNANT** **27 FURNIVAL STREET** **LONDON** **EC4A 1PQ**
	Patents ADP number *(if you know it)*	**42001** ✓

6.	If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and *(if you know it)* the or each application number	Country	Priority application number (if you know it)	Date of filing *(day/month/year)*

7.	If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application	Date of filing *(day / month / year)*

8.	Is a statement of inventorship and of right to grant of a patent required in support of this request? *(Answer 'Yes' if:* *a) any applicant named in part 3 is not an inventor, or* *b) there is an inventor who is not named as an applicant, or* *c) any named applicant is a corporate body.* *See note (d))*	**YES**

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form	**0**
Description	**40**
Claim(s)	**6**
Abstract	**0**
Drawing(s)	**7**

10. If you are also filing any of the following, state how many against each item.

Priority documents	
Translations of priority documents	
Statement of inventorship and right to grant of a patent *(Patents Form 7/77)*	
Request for preliminary examination and search *(Patents Form 9/77)*	
Request for substantive examination *(Patents Form 10/77)*	
Any other documents *(Please specify)*	

11. I/We request the grant of a patent on the basis of this application.

Signature Date

22 December 1998

12. Name and daytime telephone number of person to contact in the United Kingdom

COLM D. MURPHY
0171 404 5921

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents ct 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

a) *If you need help to fill in this form or you have any questions, please contact the Patent Office on 01645 500505.*

b) *Write your answers in capital letters using black ink or you may type them.*

c) *If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.*

d) *If you have answered 'Yes' Patents Form 7/77 will need to be filed.*

e) *Once you have filled in the form you must remember to sign and date it.*

f) *For details of the fee and ways to pay please contact the Patent Office.*

HUMAN AKT-3

The present invention is concerned with cloning and expression of a new human serine/threonine kinase termed "Akt-3" and, in particular, with nucleic acid molecules encoding the Akt-3 protein, the protein itself and compounds which can be used to inhibit cell survival, following removal of a cell from survival factors, such as, an extracellular matrix (anoikis).

A characteristic feature of many cancer cells is their ability to grow independently of adhesion. In contrast, when untransformed endothelial cells are prevented from adhering to the extracellular matrix (ECM), they undergo apoptosis (Frisch & Francis, 1994; Meredith et al, 1993). The process by which normally adherent cells are triggered to undergo apoptosis when they are unable to adhere to ECM has been termed "anoikis" (Frisch & Ruoslahti, 1997) and is an example of the effect on a cell of removal of a survival factor. Changes in signalling by adhesion molecules can lead to resistance to anoikis (Frisch & Ruoslahti 1997) and this may contribute to the mechanism whereby cancer cells that grow independently of adhesion are able to avoid anoikis.

Akt (also known as protein kinase B (PKB) or 'related to A and C protein kinase' (RAC-PK)) is a serine/threonine kinase that has been implicated in regulating cell survival (Khwaja et al., 1997; Dudek et al., 1997; Kauffmann-Zeh et al., 1997; Kennedy et al., 1997; Datta et al., 1997, Marte & Downward, 1997). Akt can inhibit apoptosis induced by detachment from ECM (anoikis; Khwaja et al., 1997), as well as by survival factor withdrawal (Kennedy et al., 1997;

Ahmed et al., 1997; Dudek et al., 1997; Kauffman-Zeh et al., 1997; Philpott et al., 1997; Crowder & Freeman, 1998; Eves et al., 1998) or irradiation (Kulik et al., 1997).

Akt comprises an NH_2-terminal pleckstrin homology (PH) domain involved in lipid binding, a kinase domain and a COOH-terminal 'tail'. Akt is thought to be activated by recruitment to the plasma membrane and subsequent phosphorylation by two upstream kinases, PDK-1 and PDK-2 (reviewed in Coffer et al, 1998; Alessi & Cohen, 1998). The binding of 3-phosphoinositides, generated by phosphatidylinositol 3-kinase (PI 3-kinase), to the PH domain of Akt is believed to promote translocation to the plasma membrane and to facilitate phosphorylation of Akt-1 by PDK-1 at Thr^{308} (Alessi et al., 1996; Alessi et al., 1997; Stephens et al., 1998) or of Akt-2 at Thr^{309} (Meier et al., 1997). In addition to phosphorylation of Thr^{308}, full activation requires phosphorylation of the COOH tail at Ser^{473} in Akt-1 (Alessi et al, 1996) or at Ser^{474} in Akt-2 (Meier et al., 1997). The enzyme responsible for phosphorylation of Ser^{473}/Ser^{474} was originally named PDK-2 but recently the integrin-linked kinase, ILK (Delcommenne et al., 1998) has emerged as a candidate for this function.

Two human isoforms of Akt have been described to date, Akt-1 and Akt-2 (Coffer & Woodgett, 1991; Jones et al., 1991; Cheng et al., 1992). A third isoform, here referred to as Akt-3, has been described in the rat (Konishi et al., 1995). Since this rat Akt-3 possesses an apparently truncated tail and thereby lacks Ser^{473}, its regulation may differ from that of Akt-1 and Akt-2. Both Akt-1 and Akt-2 are expressed widely, although the expression of Akt-2 is most prominent in insulin-

responsive tissues, such as liver and skeletal muscle (Konishi et al., 1994; Altomare et al., 1995). Akt-1 and Akt-2 are activated by insulin in rat adipocytes, hepatocytes and skeletal muscle. In contrast, Akt-3 does not appear to be strongly activated by insulin in these tissues (Walker et al., 1998). The role of the various Akt isoforms in insulin signalling may limit the utility of compounds that inhibit Akt-1 or Akt-2 activity as such agents may induce symptoms observed in patients with diabetes. We hypothesized that this problem may be avoided by using selective inhibitors of Akt-3 and this prompted us to identify the human analogue of rat Akt-3.

The present inventors have now identified and characterised a nucleic acid molecule that encodes the human isoform of Akt-3. Significantly, human Akt-3 possesses a COOH-terminal tail that contains an amino acid residue analogous to Ser^{473}/Ser^{474} previously implicated in the activation of Akt-1/Akt-2, but absent in the rat Akt-3 protein.

Therefore, there is provided by a first aspect of the present invention a nucleic acid molecule encoding human Akt-3 or a functional equivalent or bioprecursor thereof, comprising the amino acid sequence illustrated in Figure 2. Preferably, the molecule is a DNA molecule and even more preferably a cDNA molecule, and even more preferably comprises the sequence of nucleotides illustrated in Figure 1. Also provided by this aspect of the invention is a nucleic acid molecule capable of hybridising to the molecule according to the invention under high stringency conditions.

Stringency of hybridisation as used herein refers to conditions under which polynucleic acids are stable. The stability of hybrids is reflected in the melting temperature (Tm) of the hybrids. Tm can be approximated by the formula:

$$81.5°C+16.6(\log_{10}[Na^+]+0.41\ (\%G\&C)-6001/l$$

wherein l is the length of the hybrids in nucleotides. Tm decreases approximately by 1-1.5°C with every 1% decrease in sequence homology.

The nucleic acid capable of hybridising to nucleic acid molecules according to the invention will generally be at least 85%, preferably at least 90% and more preferably at least 95% homologous to the nucleotide sequences according to the invention.

The DNA molecules according to the invention may, advantageously, be included in a suitable expression vector to express polypeptides encoded therefrom in a suitable host.

The present invention also comprises within its scope proteins or polypeptides encoded by the nucleic acid molecules according to the invention or a functional equivalent, derivative or bioprecursor thereof.

An expression vector according to the invention includes a vector having a nucleic acid according to the invention operably linked to regulatory sequences, such as promoter regions, that are capable of effecting expression of said DNA fragments. The term "operably linked" refers to a juxta position wherein the components described are in a relationship

permitting them to function in their intended manner. Such vectors may be transformed into a suitable host cell to provide for expression of a polypeptide according to the invention. Thus, in a further aspect, the invention provides a process for preparing polypeptides according to the invention which comprises cultivating a host cell, transformed or transfected with an expression vector as described above under conditions to provide for expression by the vector of a coding sequence encoding the polypeptides, and recovering the expressed polypeptides.

The vectors may be, for example, plasmid, virus or phage vectors provided with an origin of replication, optionally a promoter for the expression of said nucleotide and optionally a regulator of the promoter. The vectors may contain one or more selectable markers, such as, for example, ampicillin resistance.

Regulatory elements required for expression include promoter sequences to bind RNA polymerase and transcription initiation sequences for ribosome binding. For example, a bacterial expression vector may include a promoter such as the lac promoter and for transcription initiation the Shine-Dalgarno sequence and the start codon AUG. Similarly, a eukaryotic expression vector may include a heterologous or homologous promoter for RNA polymerase II, a downstream polyadenylation signal, the start codon AUG, and a termination codon for detachment of the ribosome. Such vectors may be obtained commercially or assembled from the sequences described by methods well known in the art.

A nucleic acid molecule according to the invention may be inserted into the vectors described in an antisense orientation in order to provide for the production of antisense RNA. Antisense RNA or other antisense nucleic acids may be produced by synthetic means.

In accordance with the present invention, a defined nucleic acid includes not only the identical nucleic acid but also any minor base variations including in particular, substitutions in bases which result in a synonymous codon (a different codon specifying the same amino acid residue) due to the degenerate code in conservative amino acid substitutions. The term "nucleic acid sequence" also includes the complementary sequence to any single stranded sequence given regarding base variations.

The present invention also advantageously provides nucleic acid sequences of at least approximately 10 contiguous nucleotides of a nucleic acid according to the invention and preferably from 10 to 50 nucleotides. These sequences may, advantageously be used as probes or primers to initiate replication, or the like. Such nucleic acid sequences may be produced according to techniques well known in the art, such as by recombinant or synthetic means. They may also be used in diagnostic kits or the like for detecting the presence of a nucleic acid according to the invention. These tests generally comprise contacting the probe with the sample under hybridising conditions and detecting for the presence of any duplex or triplex formation between the probe and any nucleic acid in the sample.

According to the present invention these probes may be

anchored to a solid support. Preferably, they are present on an array so that multiple probes can simultaneously hybridize to a single biological sample. The probes can be spotted onto the array or synthesised *in situ* on the array. (See Lockhart *et al.*, Nature Biotechnology, vol. 14, December 1996 "Expression monitoring by hybridisation to high density oligonucleotide arrays". A single array can contain more than 100, 500 or even 1,000 different probes in discrete locations.

Advantageously, the nucleic acid sequences, according to the invention may be produced using such recombinant or synthetic means, such as for example using PCR cloning mechanisms which generally involve making a pair of primers, which may be from approximately 10 to 50 nucleotides to a region of the gene which is desired to be cloned, bringing the primers into contact with mRNA, cDNA, or genomic DNA from a human cell, performing a polymerase chain reaction under conditions which bring about amplification of the desired region, isolating the amplified region or fragment and recovering the amplified DNA. Generally, such techniques as defined herein are well known in the art, such as described in Sambrook *et al* (Molecular Cloning: a Laboratory Manual, 1989).

The nucleic acids or oligonucleotides according to the invention may carry a revealing label. Suitable labels include radioisotopes such as ^{32}P or ^{35}S, enzyme labels or other protein labels such as biotin or fluorescent markers. Such labels may be added to the nucleic acids or oligonucleotides of the invention and may be detected using known techniques *per se*.

A further aspect of the invention comprises human Akt-3 or a functional equivalent, derivative or bioprecursor thereof, comprising an amino acid sequence as illustrated in Figure 2.

The polypeptide designated human Akt-3 according to the invention includes all possible amino acid variants encoded by the nucleic acid molecule according to the invention including a polypeptide encoded by said molecule and having conservative amino acid changes. Polypeptides according to the invention further include variants of such sequences, including naturally occurring allelic variants which are substantially homologous to said polypeptides. In this context, substantial homology is regarded as a sequence which has at least 90% amino acid homology with the polypeptides encoded by the nucleic acid molecules according to the invention.

The nucleic acid molecule or the human Akt-3 according to the invention may, advantageously, be used as a medicament or in the preparation of a medicament, for treating diseases associated with Akt-3 expression, such as, cancer or the like.

Advantageously, the nucleic acid molecule or the polypeptide according to the invention may be provided in a pharmaceutical composition together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

The present invention is further directed to inhibiting Akt-3 *in vivo* by the use of antisense technology. Antisense technology can be used to control gene expression through triple-helix formation

or antisense DNA or RNA, both of which methods are based on binding of a polynucleotide to DNA or RNA. For example, the 5' coding portion of the mature protein sequence, which encodes for the protein of the present invention, is used to design an antisense RNA oligonucleotide of from 10 to 40 base pairs in length. A DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription (triple-helix - see Lee *et al.* Nucl. Acids Res., 6:3073 (1979); Cooney *et al.*, Science, 241:456 (1988); and Dervan *et al.*, Science, 251: 1360 (1991), thereby preventing transcription and the production of Akt-3. The antisense RNA oligonucleotide hybridises to the mRNA *in vivo* and blocks translation of an mRNA molecule into the Akt-3 (antisense - Okano, J. Neurochem., 56:560 (1991); Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988)).

Alternatively, the oligonucleotide described above can be delivered to cells by procedures in the art such that the anti-sense RNA or DNA may be expressed *in vivo* to inhibit production of Akt-3 in the manner described above.

Antisense constructs to Akt-3, therefore, may inhibit the survival promoting activity of the cell following removal of the survival factors and prevent further cancer or tumour growth.

According to a further aspect of the invention there is also provided a transgenic cell, tissue or organism comprising a transgene capable of expressing human Akt-3 protein according to the invention. The term "transgene capable of expression" as used herein means

a suitable nucleic acid sequence which leads to expression of human Akt-3 or human proteins having the same function and/or activity. The transgene, may include, for example, genomic nucleic acid isolated from human cells or synthetic nucleic acid, including DNA integrated into the genome or in an extrachromosomal state. Preferably, the transgene comprises the nucleic acid sequence encoding the proteins according to the invention as described herein, or a functional fragment of said nucleic acid. A functional fragment of said nucleic acid should be taken to mean a fragment of the gene comprising said nucleic acid coding for the proteins according to the invention or a functional equivalent, derivative or a non-functional derivative such as a dominant negative mutant, or bioprecursor of said proteins. For example, it would be readily apparent to persons skilled in the art that nucleotide substitutions or deletions may be used using routine techniques, which do not affect the protein sequence encoded by said nucleic acid, or which encode a functional protein according to the invention.

Human Akt-3 protein expressed by said transgenic cell, tissue or organism or a functional equivalent or bioprecursor of said protein also form part of the present invention.

Antibodies to human Akt-3 may, advantageously, be prepared by techniques which are known in the art. For example, polyclonal antibodies may be prepared by inoculating a host animal, such as a mouse, with human Akt-3 according to the invention or an epitope thereof and recovering immune serum. Monoclonal antibodies may be prepared according to known techniques such as

described by Kohler R. and Milstein C., Nature (1975) 256, 495-497.

Antibodies according to the invention may also be used in a method of detecting for the presence of human Akt-3 according to the invention, which method comprises reacting the antibody with a sample and identifying any protein bound to said antibody. A kit may also be provided for performing said method which comprises an antibody according to the invention and means for reacting the antibody with said sample.

Proteins which interact with the polypeptide of the invention may be identified by, for example, investigating protein-protein interactions using the two-hybrid vector system first proposed by Chien *et al* (1991).

This technique is based on functional reconstitution in vivo of a transcription factor which activates a reporter gene. More particularly the technique comprises providing an appropriate host cell with a DNA construct comprising a reporter gene under the control of a promoter regulated by a transcription factor having a DNA binding domain and an activating domain, expressing in the host cell a first hybrid DNA sequence encoding a first fusion of a fragment or all of a nucleic acid sequence according to the invention and either said DNA binding domain or said activating domain of the transcription factor, expressing in the host at least one second hybrid DNA sequence, such as a library or the like, encoding putative binding proteins to be investigated together with the DNA binding or activating domain of the transcription factor which is not incorporated in the first fusion;

detecting any binding of the proteins to be investigated with a protein according to the invention by detecting for the presence of any reporter gene product in the host cell; optionally isolating second hybrid DNA sequences encoding the binding protein.

An example of such a technique utilises the GAL4 protein in yeast. GAL4 is a transcriptional activator of galactose metabolism in yeast and has a separate domain for binding to activators upstream of the galactose metabolising genes as well as a protein binding domain. Nucleotide vectors may be constructed, one of which comprises the nucleotide residues encoding the DNA binding domain of GAL4. These binding domain residues may be fused to a known protein encoding sequence, such as for example the nucleic acids according to the invention. The other vector comprises the residues encoding the protein binding domain of GAL4. These residues are fused to residues encoding a test protein. Any interaction between polypeptides encoded by the nucleic acid according to the invention and the protein to be tested leads to transcriptional activation of a reporter molecule in a GAL-4 transcription deficient yeast cell into which the vectors have been transformed. Preferably, a reporter molecule such as ß-galactosidase is activated upon restoration of transcription of the yeast galactose metabolism genes.

A further aspect of the invention provides a method of identifying compounds which selectively inhibit human Akt-3 mediated promotion of cell survival upon withdrawal of survival factors, such survival factors including but not being limited to extracellular matrix and IgF-1, said method comprising i) providing

on the one hand a cell that survives in the presence of a survival factor but not in the absence of said survival factor unless said cell is transformed with an expression vector according to the inventionm in addition to providing as a control a cell which in the presence of survival factor has not been transformed with said vector, ii) contacting each of said cells with a test compound to ensure said compound is not toxic to said cells, iii) subsequently contacting said cells with the test compound following removal of said cells from said survival factors, wherein death of said cell when transformed with said expression vector is indicative of selective inhibition of said compound on the survival promoting human Akt-3 pathway or a parallel pathway.

Compounds which are identified according to this aspect of the invention in addition to antibodies to the human Akt-3 may, advantageously, be utilised as a medicament or alternatively in the preparation of a medicament for treating diseases associated with expression of human Akt-3 protein according to the invention.

The present invention may be more clearly understood with reference to the following example which is purely exemplary and the accompanying drawings wherein:

Figure 1 is an illustration of the cDNA sequence and deduced amino acid sequence of human Akt-3. The Akt-3 coding sequence and parts of the 5' and 3' untranslated regions are shown and numbered in the left hand column. The deduced amino acid sequence of the Akt-3 protein is shown above the corresponding DNA sequence

and is numbered in the right hand column. The two amino acid residues that are presumed to be phosphorylated upon activation of Akt-3 (Thr^{305} and Ser^{472}) are in bold and marked with an asterisk. The COOH-terminal part of the human Akt-3 protein that differs with the rat homologue is underlined.

Figure 2 is an alignment of the deduced amino acid sequences for human Akt-1, Akt-2 and Akt-3. The sequences were aligned using the ClustalW alignment program (EMBL, Heidelberg, Germany). Amino acid residues conserved between all three proteins are included in the black areas. Residues conserved between only two of the sequences are shaded in grey. Amino acid residues are numbered in the right hand column. The conserved Thr and Ser residues that are presumed to be phosphorylated upon activation are marked with an asterisk above the sequence.

Figure 3 is an illustration of phosphorylation of histone H2B by Akt-3 variants. (A) Akt-3 was expressed as a GST fusion protein in *E. Coli*. To assess hAkt-3 activity, Histone H2B was incubated with GST-Akt-3 and GST-Akt-3 variants for the indicated time and the extent of phosphorylation assessed after SDS-PAGE. The variants of Akt-3 are designated: W.T., wild type; T305D, Thr^{305} mutated to Asp; S472D, Ser^{472} mutated to Asp; T305D,S472D, both Thr^{305} and Ser^{472} mutated to Asp. No significant phosphorylation was observed when GST was used in place of GST-Akt. The results are the mean (±s.e.m.; n = 3 to 6) and are expressed relative to the extent of phosphorylation of H2B catalysed by T305D,S472D hAkt-3 after 45 minutes. *Insert*, The purity of the purified GST (lane1), wild-type Akt-3 (lane 2), T305D Akt-3 (lane 3), S472D Akt-3 (lane 4)

or T305DS472D Akt-3 (lane 5) was assessed by SDS-PAGE and by Coomassie blue staining. (B) Cos-7 cells were transfected with either vector (lanes 1 & 2) or Akt-3 (lanes 3 & 4) and either treated with buffer (lanes 1 & 3) or IGF-1 (10 ng/ml; lanes 2 and 4). Akt-3 was immunoprecipitated with antibody 12CA5 (anti-HA tag) and phosphorylation of histone 2B measured. The result shown is representative of two experiments.

Figure 4 is an illustration of inhibition of Akt-3 by staurosporine and RO 31-8220. Histone H2B was treated with Akt-3 (T305D,S472D variant) in the presence of the indicated concentrations of either staurosporine or Ro 31-8220. After 30 minutes, the reaction was terminated and the extent of H2B phosphorylation quantified on a phosphorimager following SDS-PAGE. The results (mean ±s.e.m., n=3) are expressed as relative to (%) the phosphorylation observed in the presence of solvent (control, "C").

Figure 5 is an illustration of chromosomal localisation of human Akt-3. Diagram of FISH mapping results for Akt-3. Each dot represents the double FISH signals detected on human chromosome 1, region q43-q44. Example of FISH mapping of Akt-3. The left panel shows the FISH signals on chromosome 1. The right panel shows the same mitotic figure stained with 4',6-diamidino-2-phenylindole to identify chromosome 1.

Figure 6 is an illustration of expression of Akt-3 in different human tissues.(A) Northern blot analysis of tissue expression of Akt-3. The expression of hAkt-3 mRNA in different human tissues was assessed using a probe corresponding to the 3' untranslated region of hAkt-3 to analyse a blot of human polyA$^+$ RNA

("Multiple Tissue Northern"). Human β-actin was used as a control to confirm equal loading of the lanes (data not shown). (B) and (C) RT-PCR analysis of tissue expression of Akt-3. RT-PCR analyses were performed on cDNA from different human tissues (B) and from different tumor cell lines (C) using primers specific for human Akt-3 or G3PDH (control) for the indicated number of PCR cycles. Bands of the expected size (425 bp for Akt-3 and 1 kb for G3PDH) are visible on the gels. The images from the ethidium bromide stained 1.2% agarose gels were inverted for clarity using the EagleSight software (Stratagene). The results from similar PCR reactions performed for 25, 30 or 35 cycles are not shown but indicated that the results from this figure are in the linear range of amplification. Caco-2 = colorectal adenocarcinoma; T-84 = colorectal carcinoma; MCF-7 = breast adenocarcinoma; T-47D = breast ductal gland carcinoma; HT1080 = bone fibrosarcoma; SaOS-2 = osteosarcoma; SK-N-MC = neuroblastoma; HepG2 = hepatoblastoma; JURKAT = T-cell leukemia.

MATERIALS AND METHODS

Oligonucleotide synthesis and DNA sequence determination

All primers were obtained from Eurogentec, Seraing, Belgium. Insert-specific sequencing primers (15- and 16-mers) were designed by visual inspection of the DNA sequences. DNA was prepared on Qiagen-tip-20 columns or on Qiaquick spin columns (Qiagen GmbH, Düsseldorf, Germany) and recovered from the spin columns in 30 μl Tris/EDTA-buffer (10mM TrisHCl pH 7.5, 1 mM EDTA (sodium salt)). Sequencing reactions were performed

using BigDye™ Terminator Cycle Sequencing Ready Reaction kits (Perkin Elmer, ABI Division, Foster City, CA, USA) and were run on an Applied Biosystems 377 DNA sequencer (Perkin Elmer, ABI Division, Foster City, CA, USA).

Molecular cloning of human Akt-3.

Using the rat RAC-PKγ sequence (Konishi et al., 1995; GenBank acc. no. D49836) as a query sequence, a BLAST (Basic Local Alignment Search Tool; Altschul et al., 1990) search was carried out in the WashU Merck expressed sequence tag (EST) database (Lennon et al., 1996) and in the proprietary LifeSeq™ human EST database (Incyte Pharmaceuticals Inc, Palo Alto, CA, USA). Several human EST clones with high similarity to the rat RAC-PKγ were identified. One EST sequence (Incyte accession number 2573448) derived from a hippocampal cDNA library, contained part of the coding sequence including the putative methionine start codon (ATG) and part of the 5' untranslated region. The start codon was surrounded by a Kozak consensus sequence for translation start and an in-frame stop codon was present at positions -6 to -3. Based on this 239 bp sequence, oligonucleotide sense primers were synthesised for 3' rapid amplification of cDNA ends (3' RACE) experiments: Akt-3sp1 = 5'-ACC ATT TCT CCA AGT TGG GGG CTC AG-3' and Akt-3sp2 = 5'-GGG AGT CAT CAT GAG CGA TGT TAC C-3'. 3' RACE experiments were performed on human fetal brain or human cerebellum Marathon-Ready™ cDNA (Clontech Laboratories, Palo Alto, CA, USA) according to manufacturer's instructions using Akt-3sp1/race-ap1 as primers in the primary PCR and Akt-3sp2/race-ap2 in the nested PCR. Resulting PCR fragments were cloned and sequenced. This extended the

Akt-3 coding sequence by 916 bp, but the novel sequence did not include an in-frame stop codon. A second round of 3' RACE amplification was performed on human brain Marathon Ready™ cDNA using sense primers based on the sequence obtained in the first round (Akt-3sp3 = 5'-CAC TCC AGA ATA TCT GGC ACC AGA GG-3' and Akt-3sp4 = 5'-CTA TGG CCG AGC AGT AGA CTG GTG G-3') in combination with race-ap1 and race-ap2, respectively. Now, the obtained sequence included an in-frame stop codon and the 3' untranslated sequence up to the poly(A) tail. Antisense primers were designed based on the 3' untranslated region (Akt-3ap4 = 5'-TGC CCC TGC TAT GTG TAA GAG CTA GG-3' and Akt-3ap5 = 5'-AAG AGC TAG GAC TGG TGA TGT CCA GG-3') and the complete Akt-3 coding sequence was amplified from human hippocampal cDNA using Akt-3sp1/Akt-3ap4 (primary PCR) and Akt-3sp2/Akt-3ap5 (nested PCR) as primers. The resulting 1200 bp PCR fragment was then cloned in the TA-cloning vector pCR2.1 (original TA cloning kit, Invitrogen BV, Leek, The Netherlands) and the inserts of several clones were completely sequenced. One clone containing an insert with the confirmed sequence (hAkt-3/pCR2.1) was used for subsequent subcloning to the mammalian expression vector pcDNA-3 (Invitrogen), yielding construct hAkt-3/pcDNA-3. In order to make a construct coding for a COOH-terminal tagged Akt-3 protein, a fragment of 553 bp was amplified from plasmid Akt-3/pcDNA-3 using an antisense primer incorporating a *Xho*I restriction site and the sequence coding for a hemagglutinin (HA) tag (YPYDVPDYA) after amino acid 479 of the Akt-3 sequence. This fragment was recloned into plasmid hAkt-3/pcDNA-3 using *Bst*EII and *Xho*I restriction sites yielding construct HA-hAkt-3/pcDNA-3.

Constructs and mutants for *E. coli* expression of Akt-3.

In order to express the human Akt-3 protein in *E. coli*, the complete Akt-3 coding sequence was amplified from plasmid hAkt-3/pCR2.1 using primers introducing a *Eco*RI restriction site and a *Xho*I restriction site at the 5' and 3' ends, respectively. This PCR fragment was cloned as a *Eco*RI/*Xho*I fragment in vector pGEX-4T-3 (Amersham Pharmacia Biotech, Uppsala, Sweden) yielding construct hAKT-3(WT)/pGEX-4T-3, and the sequence of the insert was confirmed by sequence analysis.

Mutants of this construct were made using the Quickchange site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) according to the manufacturer's instructions. The T305D mutant (construct hAKT-3(T305D)/pGEX-4T-3) was created by mutating ACA at position 923-925 to GAC, resulting in a Thr^{305} to Asp mutation in the resulting protein. The S472D mutant (construct hAKT-3(S472D)/pGEX-4T-3) was created by changing TC at position 1404-1405 to GA using PCR with a long antisense primer incorporating the change, resulting in a Ser^{472} to Asp mutation in the resulting protein. A double mutant was also constructed by site-directed mutagenesis on hAKT-3(S472D)/pGEX-4T-3 and contained both these mutations (construct hAKT-3(T305D/S472D)/pGEX-4T-3). The inserts of all resulting constructs were confirmed by complete sequence analysis. The fusion proteins resulting from expression of these constructs in *E. coli* contain a GST moiety coupled to the NH_2-terminus of the human Akt-3 sequence.

Expression in Cos-7 cells

Akt-3 was transiently expressed in Cos-7 by calcium phosphate transfection of the cells with the construct HA-hAkt-3/pcDNA-3. The cells were stimulated with 10 ng/ml IGF-1 for 30 minutes, lysed and Akt-3 immunoprecipitated with mAb 12CA5. Akt-3 activity was assessed as described below.

Expression and assay of wild-type and mutant Akt-3 in *E. coli*.

The expression constructs were transformed into *E. coli* strain BL21 DE3 and GST-fusion proteins of wild-type and mutated Akt-3 were purified on glutathione sepharose according to the manufacturer's instructions (Amersham Pharmacia Biotech, Uppsala, Sweden). The protein eluted from the beads was stored in 50% glycerol at -20°C. Akt activity was assessed by incubating 0.8 μg of the purified enzyme for 30 minutes at room temperature (unless otherwise indicated) in a buffer containing 10 mM HEPES, 10mM $MgCl_2$, 1 mM DTT, 0.1 mg/ml histone H2B at pH 7.0, in a total volume of 25μl and containing 10 μCi [γ-^{32}P]-ATP (6000 Ci/mmol). Initial experiments indicated that the reaction was linear with time for at least 45 minutes. The reaction was stopped by the addition of 25 μl sample buffer for SDS-PAGE. The results were quantified on a phosphorimager following SDS-PAGE on a 15% (w/v) acrylamide gel.

Chromosomal mapping studies

Chromosomal mapping studies were carried out by SeeDNA

Biotech Inc, Toronto, Canada using fluorescent *in situ* hybridisation (FISH) analysis essentially as described (Heng et al., 1992; Heng & Tsui, 1993). Briefly, human lymphocytes were cultured at 37°C for 68-72 h before treatment with 0.18 mg/ml 5-bromo-2'-deoxyuridine (BrdU) to synchronize the cell cycle in the cell population. The synchronized cells were washed and recultured at 37°C for 6 h. Cells were harvested and slides were prepared using standard procedures including hypotonic treatment, fixation and air-drying. A cDNA probe for Akt-3 (1.44 kb *Eco*RI fragment of clone hAkt-3/pcDNA-3) was biotinylated and used for FISH detection. Slides were baked at 55°C for 1 h, treated with RNase and denatured in 70% (v/v) formamide in 2x NaCl/Cit (0.3 M NaCl, 0.03 M disodium citrate, pH 7.0) for 2 min at 70°C followed by dehydration in ethanol. Probes were denatured prior to loading on the denatured chromosomal slides. After overnight hybridisation, slides were washed and FISH signals and the 4',6-diamidino-2-phenylindole banding pattern were recorded separately on photographic film, and the assignment of the FISH mapping data with chromosomal bands was achieved by superimposition of FISH signals with 4',6-diamidino-2-phenylindole banded chromosomes (Heng & Tsui, 1993).

Northern blot analysis.

Northern blots containing 2 μg of poly(A)-rich RNA derived from different human tissues (Clontech Laboratories, Palo Alto, CA, USA) were hybridised according to the manufacturer's instructions with a α-^{32}P-dCTP random-priming labelled (HighPrime kit, Boehringer Mannheim) 454 bp *Not*I-*Xba*I Akt-3 fragment (nucleotides 1404 to 1857) corresponding to part of

the 3' untranslated sequence.

Reverse transcription (RT)-PCR analysis

Oligonucleotide primers were designed for the specific PCR amplification of a fragment from Akt-3. These primers were Akt-3sp2 = 5'-GGG AGT CAT CAT GAG CGA TGT TAC C-3' (sense primer) and Akt-3ap1 = 5'- GGG TTG TAG AGG CAT CCA TCT CTT CC -3' (antisense primer), yielding a 425 bp product. PCR amplifications for human glyceraldehyde-3-phosphate dehydrogenase (G3PDH) were performed on the same cDNA samples as positive controls using G3PDH primers 5'-TGA AGG TCG GAG TCA ACG GAT TTG GT-3' (sense primer) and 5'-CAT GTG GGC CAT GAG GTC CAC CAC-3' (antisense primer), yielding a 1000 bp fragment. These primers were used for PCR amplifications on Multiple Tissue cDNA panels (Clontech Laboratories) and on cDNA prepared from tumor cell lines. For the preparation of tumor cell cDNA, cells were homogenised and total RNA prepared using the RNeasy Mini kit (Qiagen GmbH, Hilden, Germany) according to manufacturer's instructions. 1 μg of total RNA was reverse transcribed using oligo$(dT)_{15}$ as a primer and 50 U of Expand™ Reverse Transcriptase (Boehringer Mannheim, Mannheim, Germany) according to the manufacturer's instructions. PCR reactions with Akt-3-specific or G3PDH-specific primers were then performed on 1 μl of cDNA. Images of the ethidium bromide stained gels were obtained using the Eagle Eye II Video system (Stratagene, La Jolla, CA, USA) and PCR bands analysed using the EagleSight software.

RESULTS

Molecular cloning of human Akt-3.

Similarity searching of the LifeSeq™ and EMBL databases using the rat Akt-3 sequence as a query sequence yielded several human EST sequences which encoded part of the human homologue of rat Akt-3. Using the DNA sequence information in the databases, we were able in subsequent 3' RACE experiments to deduce the complete cDNA sequence for the human Akt-3 (Figure 1). The obtained cDNA sequence encoded a protein of 479 amino acid residues with a calculated molecular mass of 55770 Da. The first 451 amino acids of the human Akt-3 protein contain only two differences to the corresponding rat sequence (Konishi 1995) - Asp (rat) to Gly (human) at position 10 and Pro (rat) to Ala (human) at position 396 and encode a pleckstrin homology domain, a kinase domain and a COOH-terminal 'tail'. The predicted Akt-3 (Figure 2) protein shows significant similarity with Akt-1 (Jones et al, 1991; 83.6% identity; 87.8% similarity) and with Akt-2 (Cheng 1992; 78% identity; 84.3% similarity). The COOH-terminal 'tail' has been observed in both human and rat Akt-1 and Akt-2 proteins, but it is apparently truncated in the only other reported Akt-3 sequence (rat Akt-3, Konishi 1995; accession number D49836). 3' RACE experiments performed on human cDNAs derived from different tissues did not yield evidence for the existence of a shorter form of Akt-3 that would be analogous to the rat Akt-3 (data not shown). The tail in human Akt-3 comprises 28 amino acid residues (YDEDGMDCMDNERRPHFPQFSYSASGRE) that replace 3 amino acid residues in the rat sequence (CPL). The tail in human Akt-3 contains a serine

residue at position 472 (shown in bold) that corresponds to Ser^{473} in Akt-1 or Ser^{474} in Akt-2. Phosphorylation of Ser^{473} and Ser^{474} has previously been implicated in the activation of Akt-1 and Akt-2 , respectively (Alessi 1996; Meier 1997). Thr^{308} (in the kinase domain) has also been implicated in the activation of Akt-1 and this residue is also conserved in human Akt-3 (Thr^{305}).

Characterisation of Akt-3 activity.

To characterise the enzymatic activity of Akt-3, we expressed and purified the recombinant enzyme as a GST fusion protein. Analysis of the purified product by SDS-PAGE indicated the protein was apparently > 90% pure. The purified enzyme was able to phosphorylate histone H2B (figure 3), and no phosphorylation was observed using recombinant GST alone. Previously, the enzymatic activity of Akt-1 has been shown to be increased by phosphorylation of Thr^{308} and Ser^{473}, and mutation of both these residues to Asp (to mimic phosphorylation) synergistically activates Akt-1 (Alessi et al., 1996). To investigate whether Akt-3 is similarly regulated, GST-fusion proteins in which either Thr^{305} or Ser^{472} (corresponding to Thr^{308} and Ser^{473} in Akt-1) or both Thr^{305} and Ser^{472} had been mutated to Asp were expressed and assayed in comparison to the wild-type enzyme. Mutation of Thr^{305} to Asp ("T305D") resulted in a 2.0-fold increase in the initial rate of phosphorylation of histone H2B, whereas mutation of Ser^{472} to Asp("S472D") increased the initial rate only 1.4 fold (Figure 3A). When both Thr^{305} and Ser^{472} ("T305D,S472D") were mutated to Asp, a 3.2-fold increase in the initial phosphorylation rate was observed.

To confirm that extracellular stimuli can activate Akt-3 in mammalian cells, Cos-7 cells were transfected with a cDNA encoding Akt-3 fused to a HA tag. Akt-3 activity in HA immunoprecipitates was increased 1.5 and 1.9 fold (n=2) following stimulation with IGF-1 (10 ng/ml) (Fig 3B).

To characterise human Akt-3 further, we investigated the ability of a range of Ser/Thr kinase inhibitors to inhibit Akt-3. These included Go 6976, GF-109203X (both protein kinase C (PKC) inhibitors); H-85, H-88, H-89 and KT5720 (protein kinase A (PKA) inhibitors), KN-62 (Ca^{2+}/Calmodulin dependent kinase inhibitor) and PD 98059 (MEK inhibitor). when tested at a concentration of 10 μM these compounds had no significant effect on the activity of the T305D,S472D variant Akt-3. However, the broad spectrum kinase inhibitor staurosporine (IC_{50}= 2.0 ± 0.3 μM) and the PKC inhibitor Ro 31-8220 (IC_{50}=3.2 ± 1.0 μM) inhibited theT305D,S472D variant of Akt-3 (Figure 4).

Chromosomal localisation of Akt-3.

The complete coding sequence of Akt-3 was used as a probe for FISH analysis. Under the conditions used, the hybridisation efficiency was approximately 75% for this probe (among 100 checked mitotic figures, 75 of them showed signals on one pair of the chromosomes). Since the DAPI-banding was used to identify the specific chromosome, the assignment between the signal from the probe and the long arm of chromosome 1 was obtained. The detailed position was further determined in the diagram based upon the summary from 10 photographs (Figure 5A). There was no additional locus picked by FISH detection under the conditions used,

therefore, we conclude that Akt-3 is located at human chromosome 1, region q43-q44. An example of the mapping results is presented in Figure 5 B.

Tissue distribution of Akt-3 mRNA.

Northern blot analysis was performed on mRNA derived from different human tissues. Akt-3 mRNA was detected as two transcripts of approximately 4.5 kb and 7.5 kb, showing similar patterns of expression (Fig. 6A). Akt-3 mRNA was expressed in a range of tissues, most prominently in brain. Similarly, rat Akt-3 was detected as multiple transcripts most highly expressed in brain (Konishi et al., 1995). The weakest expression of Akt-3 was observed in two insulin-responsive tissues, skeletal muscle and liver. Akt-3 was also expressed in a number of cancer cell lines including SW480 colorectal adenocarcinoma, A549 lung carcinoma and G361 Melanoma (data not shown).

To confirm the Northern blot analysis, PCR reactions were performed with Akt-3 specific and G3PDH-specific (internal control) primers on cDNAs derived from different human tissues (Fig. 6B). The Akt-3 message was present in every tissue tested, since a specific 425 bp fragment was amplified in every cDNA after 30 cycles of PCR. Akt-3 mRNA expression was high in placenta, ovary and spleen. Moderate expression was seen in brain, heart, kidney, colon, prostate, small intestine and testis. Lowest expression was in liver, lung, pancreas, skeletal muscle, peripheral blood leukocytes and thymus. In tumor cell lines (Figure 6C), Akt-3 mRNA expression was relatively high in HT-1080 bone fibrosarcoma cells, in SaOS-2 osteosarcoma and in JURKAT T-cell leukemia cells (Akt-3 band

detectable after 30 cycles of PCR). Caco-2 colorectal adenocarcinoma, T84 colorectal carcinoma, MCF-7 breast adenocarcinoma and SK-N-MC neuroblastoma cells show Akt-3 mRNA expression after 35 cycles of PCR. In T-47D breast ductal gland carcinoma and HepG2 hepatoblastoma, expression of Akt-3 mRNA is very low or absent (no signal detectable after 35 cycles of PCR).

Akt-1 and Akt-2 have been identified in several species. Human (Jones et al., 1991; Coffer et al 1991), mouse (Bellacosa et al., 1993) and bovine (Coffer &Woodgett, 1991) Akt-1 clones have been reported, whereas human (Cheng et al., 1992) mouse (Altomare et al., 1995) and rat (Konishi et al., 1994) clones of Akt-2 have been identified. However, Akt-3 has only been previously identified in rat (Konishi et al, 1995). We have identified the human isoform of Akt-3. Although human Akt-3 shows considerable similarity to human Akt-1 and Akt-2, the discovery of human Akt-3 is particularly significant because the cDNA sequence encodes a COOH-terminal 'tail' which includes a phosphorylation site implicated in the activation of Akt-1 and Akt-2 (Alessi et al., 1996; Meier et al., 1997). This tail is absent from the predicted rat amino acid sequence. Human Akt-3 appears to be activated by phosphorylation in a similar fashion as Akt-1 and Akt-2. However, its expression profile suggests that the principal function of this enzyme is not in regulating responses to insulin.

The sequence we have identified represents the human homologue of Akt-3. This assignment is based on the >99% identity between the rat and human Akt-3 protein sequences. With the exception of the COOH-terminal

tail seen in human Akt-3, there are only 2 amino acid differences (Gly^{10} and Ala^{396} in human Akt-3) between the rat and human Akt-3 proteins. Alignment of all the previously described Akt sequences demonstrates that Gly^{10} and Ala^{396} in the human protein correspond to Gly and Ala residues respectively in the Akt-1 and Akt-2 sequences identified from other species. Further evidence that we have identified the Akt-3 isoform comes from the presence of isotype-specific sequences represented by human Akt-3 residues 47-49 (LPY), 118-122 (NCSPT) and 139-141 (HHK). For each isotype, these sequences are conserved between species, but differ between the isotypes.

The human Akt-3 cDNA sequence was predicted to encode a NH_2-terminal pleckstrin homology (PH) domain (Musacchio et al., 1993) and a COOH-terminal kinase domain. A striking difference between the human and rat Akt-3 protein sequence (Konishi, 1995) is the presence of a COOH-terminal 'tail' comprising 74 residues after the kinase domain. The last 28 amino acid residues in human Akt-3 are absent from the rat Akt-3 sequence. We were unable to identify human cDNA sequences that encoded a similar truncation, despite conducting RACE experiments using cDNA from several different human tissues. The region in human Akt-3 that is absent from rat Akt-3 encompasses a stretch of 10 residues (residues 467-476 in human Akt-3) which are identical to the corresponding region of human Akt-1 and Akt-2. This suggests that the tail observed in human Akt-3 is authentic. The significance of the difference observed in the rat Akt-3 tail region remains to be investigated. However, the human Akt-3 COOH-terminal sequence includes Ser^{472}, which corresponds to Ser^{473} in Akt-1. Phosphorylation of

Ser^{473} has been shown to lead to a 5-fold increase in the activity of Akt-1, whereas a 20-25 fold increase of Akt-1 activity is observed if both Ser^{473} and Thr^{308} are phosphorylated (Alessi et al., 1996). Thus, our observation that Ser^{472} is present in human Akt-3 is significant, because it suggests that human Akt-3 is potentially regulated in a manner similar to Akt-1 and Akt-2. Whether rat Akt-3 is regulated in a different fashion remains to be resolved.

The kinase and PH domains in Akt-3 show homology to the consensus PH and kinase domain sequences (Musacchio et al, 1993; Hanks & Hunter 1995). The PH domain of human Akt-3 is 77% and 86% identical to the PH domains in Akt-1 and Akt-2, respectively, while the kinase domain of Akt-3 is 88% and 87% identical to the kinase domain of Akt-1 and Akt-2, respectively. The high conservation of the PH domain may indicate an Akt-specific function, because PH domains are often highly divergent (Musacchio et al, 1993). Apart from binding phosphoinositides, the PH domain of Akt has been shown to mediate interactions between Akt and PKC (Konishi, 1995) as well as directing the formation of multimeric Akt complexes (Datta et al, 1995). In contrast, the region between the PH domain and the kinase domain is poorly conserved between the human Akt-1, Akt-2 and Akt-3 sequences, and this region is also important for mediating the formation of multimeric Akt complexes (Datta et al, 1995). This raises an interesting issue - whether the sequence NH_2-terminal to the kinase domain of Akt-3 mediates the interaction with binding partners that are unique to Akt-3 or that bind to multiple Akt isoforms.

To verify that the predicted kinase domain was

catalytically active, we expressed Akt-3 as a GST fusion protein in *E. Coli*. The purified protein was able to phosphorylate an exogenous substrate, whereas no catalytic activity was observed using GST in place of GST-Akt-3. To confirm that Akt-3 is indeed regulated in a manner akin to Akt-1 and Akt-2, we mutated Thr^{305} and Ser^{473}, either separately or jointly, to Asp. This strategy has previously been shown to faithfully mimic the effect of phosphorylation of these residues in Akt-1 (Alessi et al., 1996). Mutation of either of these residues resulted in increased activity, although the increase was less than that observed with Akt-1 (Alessi et al., 1996). Additionally, we did not observe a synergistic activation of Akt-3 by mutation of both Thr^{305} and Ser^{473}. In contrast, when both the corresponding residues were simultaneously mutated to Asp in Akt-1, synergistic activation was observed (Alessi et al, 1996). The apparent quantitative differences between Akt-1 and Akt-3 may reflect true differences in the regulation of these two isoforms, or it may be due to other factors such as the different expression system used. In the present study Akt-3 was expressed as a GST fusion protein in *E. Coli*, whereas Akt-1 activity was studied using an HA-tagged protein expressed in COS cells. Nevertheless, our results demonstrate that Akt-3 is qualitatively regulated in a fashion similar to Akt-1. Previous work has also shown that activation of Akt is dependent upon PI 3-kinase to generate 3-phosphoinositides that bind the PH domain of Akt, promote translocation of Akt to the plasma membrane and facilitate the phosphorylation of Akt by upstream kinases (reviewed in Alessi & Cohen, 1998; Coffer et al., 1998). Our observation that the T305D/S472D mutant of Akt-3 is more active than the wild type

enzyme (Figure 3), when measured in the absence of 3-phosphoinositides, suggests that after phosphorylation Akt-3 becomes (at least partially) independent of phosphoinositide binding.

The structure of the catalytic domain of Akt is closely related to Protein kinase A and Protein kinase C. Indeed, a BLAST search of the SwissProt data base revealed that the most closely related kinases (other than the different Akt isoforms) include several protein kinase C isozymes. This prompted us to investigate whether existing inhibitors of PKA or PKC, as well as other serine/threonine kinase inhibitors, could be used as inhibitors of Akt-3. Of the compounds tested, only staurosporine and the structurally related compound Ro 31-8220 both potently inhibited Akt-3. Staurosporine is a non-selective kinase inhibitor, whereas Ro 31-8220 is a more selective PKC inhibitor (Davis, 1992). Although Ro 31-8220 is an approximately 100-fold more potent (IC_{50}≈10 nM; Davis, 1992) inhibitor of PKC than of Akt-3, this observation cautions that experiments using high concentrations of Ro 31-8820 may affect Akt-3. In contrast to staurosporine and Ro 31-8220, two other PKC inhibitors and three other PKA inhibitors did not inhibit Akt-3. This suggests that although Akt-3 is closely related in sequence to PKC, it may be possible to find selective inhibitors of Akt.

The observation that Akt-3 is activated by IGF-1 suggests that Akt-3 may play a role in regulating cell survival. Akt-3 potentially may suppress apoptosis in tumor cells. One concern in using Akt as a target for drug development in cancer is that Akt plays a role in insulin signalling (reviewed in Sheperd et al, 1998).

Thus, inhibitors of Akt may induce symptoms observed in patients with diabetes. One solution that has been proposed is to develop selective inhibitors of Akt-2 (Walker et al, 1998). This is based in part on the observation that Akt-1 is strongly activated by insulin in rat hepatocytes and skeletal muscle, whereas Akt-2 is only weakly activated by insulin in these tissues. However, rat Akt-3 appears to be even more weakly activated by insulin in these tissues (Walker et al, 1998), and in this study we have shown that Akt-3 mRNA is expressed only at low levels in human liver and skeletal muscle, which are insulin responsive tissues. This suggests that selective inhibitors of Akt-3 could have even less potential to cause symptoms similar to those seen in patients with diabetes than do inhibitors of Akt-2. The localisation of human Akt-3 to human chromosome 1q43-44 is also interesting, as patients with haematological cancers have been reported with chromosomal abnormalities in this region (Mitelman et al, 1997). Although the significance of the latter observation is debatable, as chromosomal abnormalities at numerous loci have been observed in patients with haematological cancers, the results presented here indicate that Akt-3 may prove to be an important target for the development of novel therapeutics for the treatment of cancer.

REFERENCES

Ahmed, N.N, Grimes, H. L., Bellacosa, A., Chan, T. O., Tsichlis (1997) Transduction of interleukin-2 antiapoptotic and proliferative signals via Akt protein kinase. *Proc. Natl Acad Sci USA 94*, 3627-3632.

Alessi, D.R. & Cohen, P. (1998) Mechanism of activation and function of protein kinase B. *Current Opinion Gen. Dev. 8*, 55-62.

Alessi, D.R., Andjelkovic, M., Caudwell, F.B., Cron, P., Morrice, N., Cohen, P. & Hemmings, B. (1996) Mechanism of activation of protein kinase B by insulin and IGF1. *EMBO J. 15*, 6541-6551.

Alessi, D.R., Deak, M., Casamayor, A., Caudwell, F.B., Morrice, N., Norman, D.G., Gaffney, P., Reese, C.B., MacDougall, C.N., Harbison, D., Ashworth, A. & Bownes, M. (1997) 3-phosphoinositide-dependent protein kinase-1 (PDK-1): structural and functional homology with the *Drosophila* DSTP61 kinase. *Curr. Biol.* 7:776-789.

Altomare, D.A, Guo, K, Cheng, J. Q., Sonoda, G., Walsh, K. & Testa, J.R., (1995) Cloning, chromosomal localisation and expression analysis of the mouse Akt2 oncogene. *Oncogene 11*, 1055-1060.

Altschul, S.F., Gish, W., Miller, W., Myers, E.W. & Lipman, D.J. (1990). Basic local alignment search tool, *J. Mol. Biol. 215,* 403 - 410.

Bellacosa, A., Franke, T.F., Gonzalez-Portal, M.E., Detta, K., Taguchi, T., Gardner, J., Cheng, J.Q.,

Testa, J.R. & Tsichlis, P.N. (1993) Structure, expression and chromosomal mapping of c-akt: relationship to v-akt and its implications. *Oncogene 8*, 745-754.

Bellacosa, A., De Feo, D., Godwin, A.K., Bell, D.W., Cheng, J.Q., Altomare, D.A., Wan, M., Dubeau, L., Scambia, G., Masciullo, V., Ferrandina, G., Benedetti Panicini, P., Mancuso, S., Neri, G. & Testa, J.R. (1995) Molecular alterations of the Akt2 oncogene in ovarian and breast cancer, *Int. J. Cancer 64*, 280-285.

Cheng, J.Q., Godwin, A.K., Bellacosa, A., Taguchi, T., Franke, T.F., Hamilton, T.C., Tsichlis, P.N. & Testa, J.R. (1992) AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. *Proc. Natl. Acad. Sci. USA 89*, 9267-9271.

Coffer, P.J. & Woodgett, J.R. (1991) Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families. *Eur. J. Biochem. 201*, 475-481.

Coffer, P.J., Jin, J. & Woodgett, J.R. (1998) Protein kinase B (c-Akt) - A multifunctional mediator of phosphatidylinositol 3-kinase activation. *Biochem. J. 335*:1-13.

Cohen, P., Alessi, D.R. & Cross, D.A.E. (1997) PDK1, the missing link in insulin signal transduction? *FEBS Lett. 410*, 3-10.

Crowder, R.J. & Freeman, R.S. (1998)

Phosphatidylinositol 3-kinase and Akt protein kinase are necessary and sufficient for the survival of nerve growth factor-dependent sympathetic neurons, *J. Neurosci. 18*, 2933-2943.

Datta, S.R., Dudek, H., Tao, X., Masters, S., Fu, H.A., Gotoh, Y. & Greenberg, M.E. (1997) Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. *Cell 91*, 231-241.

Davis, P.D., Elliot L.H., Harris, W., Hill, C.H., Hurst, S.A., Keech, E., Kumar, M.K., Lawton, G., Nixon, J.S. & Wilkinson, W.E. (1992) Inhibitors of protein kinase C. 2. Substituted bisindoylmaleimides with improved potency and selectivity. *J. Med. Chem. 35*, 994-1001.

del Peso, L., Gonzalez-Garcia, M., Page, C., Herrera, R., Nunez, G., (1997) Interleukin-3- induced phosphorylation of BAD through the protein kinase Akt. *Science 278*, 687-689.

Delcommenne, M., Tan, C., Gray, V., Rue, L., Woodgett, J. & Dedhar, S. (1998) Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. *Proc. Natl. Acad. Sci. USA 95,* 11211-11216.

Dudek, H., Datta, S.R., Franke, T.F., Bimbarun, M.J., Yao, R., Cooper, G.M., Segal, R.A., Kaplan, D.R. & Greenberg, M.E. (1997) Regulation of neuronal survival by the serine-threonine protein kinase Akt. *Science 275*, 661-665.

Eves, E.M., Xiong, W., Bellacosa, A., Kennedy, S.G.,

Tsichlis, P.N., Rosner, M.R. & Hay, N.(1998) Akt, a target of phosphatidylinositol 3-kinase, inhibits apoptosis in a differentiating neuronal cell line. *Mol. Cell. Biol. 18*, 2143-2152.

Frisch S.M. & Francis, H. (1994) Disruption of epithelial cell-matrix interactions induces apoptosis, *J. Cell. Biol. 124*, 619-626

Frisch, S.M. & Ruoslahti, E. (1997) Integrins and Anoikis. *Curr. Op. Cell. Biol. 9*, 701-706

Hanks, S.K. & Hunter, T. (1995) The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification *FASEB J.9*, 576-596.

Hemmings, B.A. (1997) Akt signaling: linking membrane events to life and death decisions. *Science 275*, 628-630.

Heng, H.H.Q. & Tsui, L.-C. (1993) Modes of DAPI banding and simultaneous *in situ* hybridization. *Chromosoma 102,* 325-332.

Heng, H.H.Q., Squire, J. & Tsui, L.-C. (1992) High resolution mapping of mammalian genes by *in situ* hybridization to free chromatin. *Proc. Natl. Acad. Sci. USA 89,* 9509-9513.

Jones, P.F., Jakubowicz, T., Pitossi, F.J., Maurer, F. & Hemmings, B.A. (1991) Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily. *Proc. Natl. Acad. Sci. USA 88*, 4171-4175.

Kauffmann-Zeh, A., Rodriquez-Viciana P., Ulrich, E., Gilbert, C., Coffer, P., Downward, J. & Evan, G. (1997) Suppression of c-Myc-induced apoptosis by ras signalling through PI(3)K and PKB. *Nature 385*, 544-548.

Kennedy, S.G., Wagner, A.J., Conen, S.D., Jordan, J., Bellacosa, A., Tsichlis, A.N. & Hay, N. (1997) The PI 3-kinase/Akt signalling pathway delivers an anti-apoptotic signal. *Genes & Development 11*, 701-713.

Khwaja, A., Rodriguez-Viciana, P., Wennstrom, S., Warne, P.H. & Downward, J. (1997) Matrix adhesion and ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. *EMBO J. 16*, 2783-2793.

Konishi, H., Shinomuara, T., Kuroda, S., Ono, Y. & Kikkawa, U. (1994) Molecular Cloning of rat RAC protein kinase α and β and their association with protein kinase Cζ. *Biochem. Biophys. Res. Commn 205*, 817-825.

Konishi, H., Kuroda, S., Tanaka, M., Matsuzaki, H., Ono, Y., Kameyama, K., Haga, T. & Kikkawa, U. (1995) Molecular cloning and characterisation of a new member of the RAC protein kinase family: association of the pleckstrin homology domain of three types of RAC protein kinase with protein kinase C subspecies and βγ subunits of G proteins. *Biochem. Biophys. Res. Commun. 216*, 526-534.

Konishi, H., Shinomuara, T., Kuroda, S., Ono, Y., Kikkawa, U., (1994) Molecular Cloning of rat RAC protein kinase α and β and their association with

protein kinase Cζ *Biochem. Biophys. Res. Commn, 205,* 817-825.

Kulik, G., Klippel, A. & Weber, M.J. (1997) Anti-apoptotic signalling by the insulin-like growth factor receptor, phosphatidylinositol-3 kinase and Akt. *Mol. Cell. Biol. 17,* 1595-1606.

Lennon, G., Auffray, C., Polymeropoulos, M. & Soares, M.B. (1996) The I.M.A.G.E. Consortium: an integrated molecular analysis of genomes and their expression. *Genomics 33,* 151-152.

Marte, B.M. & Downward, J. (1997) PKB/Akt: connecting phosphoinositide 3-kinase to cell survival and beyond. *Trends Biochem. Sci. 22,* 355-358.

Marte, B.M., Rodriquez-Viciana, P., Wennstrom, S., Warne, P.H. & Downward, J. (1997) R-Ras can activate the phosphoinositide 3-kinase but not the MAP kinase arm of the Ras effector pathways (1997) *Curr. Biol.* 7, 63-70.

Meier, R., Alessi, D.R., Cron, P., Andjelkovic, M. & Hemmings, B.A. (1997) Mitogenic activation, phosphorylation and nuclear translocation of protein kinase β. *J. Biol. Chem. 272,* 30491-30497.

Meredith J.E. Jr., Frazeli, B.& Schwartz, M.A.. (1993) The extracellular matrix as a survival factor, *Mol. Cell Biol 4,* 953-961.

Mitelman, F., Mertens F. & Johansson, B., (1997) A breakpoint map of recurrent chromosomal rearrangements in human neoplasia., *Nature Genetics 15,* 417-474.

Musacchio, A., Gibson, T., Rice. P,, Thompson, J. & Saraste, M. (1993) The PH domain: a common piece in the structural patchwork of signalling proteins. *Trends Biochem. Sci 18*, 343-348.

Philpott, K.L., McCarthy, M.J., Klippel, A. & Rubin, L.L. (1997) Activated phosphatidylinositol 3-kinase and Akt kinase promote survival of superior cervical neurons. *J. Cell. Biol. 139*, 809-815.

Sheperd, P.R., Withers, D.J. & Siddle, K. (1998) Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling. *Biochem J. 333*, 471-490.

Stephens, L., Anderson, K., Stokoe, D., Erdjumentbromage, H., Painter, G.F., Holmes, A.B., Gaffney, P.R.J., Reese, C.B., McCormick, F., Tempst, P., Coadwell, J. & Hawkins, P.T. (1998) Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. *Science,* 279, 710-714.

Staal, S.P. (1987) Molecular cloning of the *akt* oncogene and its human homologues AKT! And AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. *Proc. Natl. Acad Sci. USA 89*, 9267-9271.

Stokoe, D., Stephens, L.R., Copeland, T., Gaffney, P.R.J., Reese, C.B. & Painter, G.F. (1997) Dual role of phosphatidylinositol-3,4,5-triphosphate in the activation of protein kinase B. *Science 277*, 567-570.

Walker, K.S., Deak, M., Paterson, A., Hudson, K., Cohen, P. & Alessi, D.R. (1998) Activation of protein

kinase B β and γ isoforms by insulin *in vivo* and by 3-phosphoinositide-dependent protein kinase-1 *in vitro*: comparison with protein kinase B α. *Biochem. J. 331*, 299-308.

5

CLAIMS

1. A nucleic acid molecule encoding human Akt-3 or a functional equivalent or bioprecursor thereof, comprising the amino acid sequence illustrated in Figure 2.

2. A nucleic acid molecule according to claim 1 which is a DNA molecule, and preferably cDNA.

3. An nucleic acid molecule according to claim 1 or 2 comprising the nucleotide sequence illustrated in Figure 1.

4. An antisense molecule capable of hybridising to the molecule according to any of claims 1 to 3 under high stringency conditions.

5. Human Akt-3 or a functional equivalent, derivative or bioprecursor thereof, comprising an amino acid sequence as illustrated in Figure 2.

6. Human Akt-3 or a functional equivalent, derivative or bioprecursor thereof encoded by a nucleic acid molecule according to any of claims 1 to 3.

7. Human Akt-3 according to claim 6 comprising the amino acid sequence as illustrated in Figure 2.

8. An expression vector comprising a nucleic acid molecule according to claim 2 or 3.

9. An expression vector according to claim 8 comprising an inducible promoter.

10. An expression vector according to claim 8 or 9 comprising a sequence encoding a reporter molecule.

11. A nucleic acid molecule according to any of claims 1 to 4 for use a medicament.

12. A nucleic acid molecule according to any of claims 1 to 4 in the preparation of a medicament for treating cancer.

13. Human Akt-3 according to any of claims 5 to 7 for use as a medicament.

14. Use of human Akt-3 according to any of claims 5 to 7 in the preparation of a medicament for treating cancer.

15. A pharmaceutical composition comprising a nucleic acid molecule according to any of claims 1 to 4 or a human Akt-3 according to any of claims 5 to 7 together with a pharmaceutically acceptable carrier diluent or excipient therefor.

16. A host cell or organism, transformed or transfected with an expression vector according to any of claims 8 to 10.

17. A transgenic cell, tissue or organism comprising a transgene capable of expressing human Akt-3 according to any of claims 5 to 7.

18. A human Akt-3 protein expressed from the cell or organism according to claim 16 or 17.

19. An antibody capable of binding to human Akt-3 or

an epitope thereof according to any of claims 5 to 7.

20. An antibody according to claim 19 which is a monoclonal antibody.

21. An antibody according to claim 19 or 20 for use as a medicament.

22. Use of an antibody according to claim 19 or 20 in the preparation of a medicament for treating cancer, or other diseases or conditions associated with human Akt-3 expression.

23. A kit for detecting human Akt-3 in a sample having a sequence according to any of claims 5 to 7, which kit comprises an antibody according to claim 19 or 20 and means for contacting said antibody with said sample.

24. A method of identifying compounds which selectively inhibit human Akt-3 mediated promotion of cell survival upon withdrawal of survival factors, said method comprising:

i) providing on the one hand a cell that survives in the presence of a survival factor but not in the absence of said survival factor unless said cell is transformed with an expression vector according to any of claims 8 to 10, in addition to providing a cell which in the presence of said survival factor has not been transformed with said vector,

ii) contacting each of said cells with a test compound to ensure said compound is not toxic to said cells, iii) subsequently

contacting each of said cells with the test compound following the removal of said cells from said survival factors, wherein death of said cell when transformed with said expression vector is indicative of selective inhibition of said compound on the survival promoting Akt-3 pathway or a parallel pathway.

25. A compound identifiable according to the method of claim 24.

26. A compound according to claim 25 for use as a medicament.

27. Use of a compound according to claim 25 in the manufacture of a medicament for treating diseases associated with human Akt-3 expression.

28. A method of identifying agents which influence the activity of a human Akt-3 protein according to any of claims 5 to 7, said method comprising contacting said human Akt-3 with a substrate therefor in the presence of a test compound and a phosphate source, and monitoring for any phosphorylation of said substrate.

29. A method according to claim 28 wherein said Akt-3 is provided as a fusion or epitope tagged protein having a domain capable of phosphorylating a known substrate.

30. A method according to claim 26 wherein said Akt-3 is provided as a fusion molecule of GST and human Akt-3 according to the invention.

31. A method of identifying agents which influence the activity of human Akt-3 protein according to any of claims 5 to 7, said method comprising contacting a phospholipid or a surrogate or functional equivalent thereof, with a PH domain of a human Akt-3 protein according to any of claims 5 to 7 in the presence of an agent to be tested and monitoring for any binding of said phospholipid, surrogate or functional equivalent thereof with said PH domain of said Akt-3 protein.

32. A method according to claim 31 wherein said phospholipid comprises phosphatidylinositol 3, 4, 5 - triphosphate.

33. An agent identifiable according to the method of claim 31 or 32.

34. An agent according to claim 33 for use as a medicament.

35. Use of an agent according to claim 33 in the preparation of a medicament for treating diseases associated with human Akt-3 expression.

36. A method of treating diseases associated with human Akt-3 expression said method comprising administering to an individual suffering from said disease a compound that inhibits the function or expression of human Akt-3 according to any of claims 5 to 7, in a sufficient concentration to reduce the symptoms of said disease.

37. A method according to claim 36 wherein said compound is any of an antisense molecule according to

claim 4, an antibody according to claim 20 or 21, a compound according to claim 23 or an agent according to claim 33.

38. A method for making a pharmaceutical formulation for the treatment of diseases associated with human Akt-3 expression, said method comprising:

a) contacting candidate compounds with a host cell that expresses human Akt-3 protein,

b) selecting a compound identified in step a) which binds to human Akt-3 protein,

c) manufacturing bulk quantities of the compound selected in step b), and

d) formulating the compound manufactured in step c) in a pharmaceutically acceptable carrier.

```
                  M  S  D  V  T  I  V  K  E  G  W  V  Q  K  R  G  E   17
1 GGGAGTCATCATGAGCGATGTTACCATTGTGAAAGAAGGTTGGGTTCAGAAGAGGGGAGA

   Y  I  K  N  W  R  P  R  Y  F  L  L  K  T  D  G  S  F  I  G   37
61 ATATATAAAAAACTGGAGGCCAAGATACTTCCTTTTGAAGACAGATGGCTCATTCATAGG

   Y  K  E  K  P  Q  D  V  D  L  P  Y  P  L  N  N  F  S  V  A   57
121 ATATAAAGAGAAACCTCAAGATGTGGATTTACCTTATCCCCTCAACAACTTTTCAGTGGC

   K  C  Q  L  M  K  T  E  R  P  K  P  N  T  F  I  I  R  C  L   77
181 AAAATGCCAGTTAATGAAAACAGAACGACCAAAGCCAAACACATTTATAATCAGATGTCT

   Q  W  T  T  V  I  E  R  T  F  H  V  D  T  P  E  E  R  E  E   97
241 CCAGTGGACTACTGTTATAGAGAGAACATTTCATGTAGATACTCCAGAGGAAAGGGAAGA

   W  T  E  A  I  Q  A  V  A  D  R  L  Q  R  Q  E  E  E  R  M  117
301 ATGGACAGAAGCTATCCAGGCTGTAGCAGACAGACTGCAGAGGCAAGAAGAGGAGAGAAT

   N  C  S  P  T  S  Q  I  D  N  I  G  E  E  E  M  D  A  S  T  137
361 GAATTGTAGTCCAACTTCACAAATTGATAATATAGGAGAGGAAGAGATGGATGCCTCTAC

   T  H  H  K  R  K  T  M  N  D  F  D  Y  L  K  L  L  G  K  G  157
421 AACCCATCATAAAAGAAAGACAATGAATGATTTTGACTATTTGAAACTACTAGGTAAAGG

   T  F  G  K  V  I  L  V  R  E  K  A  S  G  K  Y  Y  A  M  K  177
481 CACTTTTGGGAAAGTTATTTTGGTTCGAGAGAAGGCAAGTGGAAAATACTATGCTATGAA

   I  L  K  K  E  V  I  I  A  K  D  E  V  A  H  T  L  T  E  S  197
541 GATTCTGAAGAAAGAAGTCATTATTGCAAAGGATGAAGTGGCACACACTCTAACTGAAAG

   R  V  L  K  N  T  R  H  P  F  L  T  S  L  K  Y  S  F  Q  T  217
601 CAGAGTATTAAAGAACACTAGACATCCCTTTTTAACATCCTTGAAATATTCCTTCCAGAC

   K  D  R  L  C  F  V  M  E  Y  V  N  G  G  E  L  F  F  H  L  237
661 AAAAGACCGTTTGTGTTTTGTGATGGAATATGTTAATGGGGGCGAGCTGTTTTTCCATTT

   S  R  E  R  V  F  S  E  D  R  T  R  F  Y  G  A  E  I  V  S  257
721 GTCGAGAGAGCGGGTGTTCTCTGAGGACCGCACACGTTTCTATGGTGCAGAAATTGTCTC

   A  L  D  Y  L  H  S  G  K  I  V  Y  R  D  L  K  L  E  N  L  277
781 TGCCTTGGACTATCTACATTCCGGAAAGATTGTGTACCGTGATCTCAAGTTGGAGAATCT

   M  L  D  K  D  G  H  I  K  I  T  D  F  G  L  C  K  E  G  I  297
841 AATGCTGGACAAAGATGGCCACATAAAAATTACAGATTTTGGACTTTGCAAAGAAGGGAT
                         *
   T  D  A  A  T  M  K  T  F  C  G  T  P  E  Y  L  A  P  E  V  317
901 CACAGATGCAGCCACCATGAAGACATTCTGTGGCACTCCAGAATATCTGGCACCAGAGGT

   L  E  D  N  D  Y  G  R  A  V  D  W  W  G  L  G  V  V  M  Y  337
961 GTTAGAAGATAATGACTATGGCCGAGCAGTAGACTGGTGGGGCCTAGGGGTTGTCATGTA

   E  M  M  C  G  R  L  P  F  Y  N  Q  D  H  E  K  L  F  E  L  357
1021 TGAAATGATGTGTGGGAGGTTACCTTTCTACAACCAGGACCATGAGAAACTTTTTGAATT

   I  L  M  E  D  I  K  F  P  R  T  L  S  S  D  A  K  S  L  L  377
1081 AATATTAATGGAAGACATTAAATTTCCTCGAACACTCTCTTCAGATGCAAAATCATTGCT

   S  G  L  L  I  K  D  P  N  K  R  L  G  G  G  P  D  D  A  K  397
1141 TTCAGGGCTCTTGATAAAGGATCCAAATAAACGCCTTGGTGGAGGACCAGATGATGCAAA

   E  I  M  R  H  S  F  F  S  G  V  N  W  Q  D  V  Y  D  K  K  417
1201 AGAAATTATGAGACACAGTTTCTTCTCTGGAGTAAACTGGCAAGATGTATATGATAAAAA

   L  V  P  P  F  K  P  Q  V  T  S  E  T  D  T  R  Y  F  D  E  437
1261 GCTTGTACCTCCTTTTAAACCTCAAGTAACATCTGAGACAGATACTAGATATTTTGATGA

   E  F  T  A  Q  T  I  T  I  T  P  P  E  K  Y  D  E  D  G  M  457
1321 AGAATTTACAGCTCAGACTATTACAATAACACCACCTGAAAAATATGATGAGGATGGTAT
                                        *
   D  C  M  D  N  E  R  R  P  H  F  P  Q  F  S  Y  S  A  S  G  477
1381 GGACTGCATGGACAATGAGAGGCGGCCGCATTTCCCTCAATTTTCCTACTCTGCAAGTGG

   R  E                                                        479
1441 ACGAGAATAAGTCTCTTTCATTCTGCTACTTCACTGTCATCTTCAATTTATTACTGAAAA

1501 TGATTCCTGGACATCACCAGTCCTAGCTCTTACACATAGCAGGGGCA
```

Fig 1


Akt-1 : MSDVAIVKEGWLHKRGEYIKTWRPRYFLLKNDGTFIGYKERPQDVDQREAPLNNFSVAQCQLMKTERPRPNTFIIRCLQWTTVIERTFHV : 90
Akt-2 : MNEVSVIKEGWLHKRGEYIKTWRPRYFLLKSDGSFIGYKERPEAPDQTLPPLNNFSVAECQLMKTERPRPNTFVIRCLQWTTVIERTFHV : 90
Akt-3 : MSDVTIVKEGWVQKRGEYIKNWRPRYFLLKTDGSFIGYKEKPQDVDLP-YPLNNFSVAKCQLMKTERPKPNTFIIRCLQWTTVIERTFHV : 89
Akt-1 : ETPEEREEWTTAIQTVADGLKKQE--EEEMDFRSGSPSDNSGAEEMEVSLAKPKHRVTMNEFEYLKLLGKGTFGKVILVKEKATGRYYAM : 178
Akt-2 : DSPDEREEWMRAIQMVANSLKQRAPGEDPMDYKCGSPSDSSTTEEMEVAVSKARAKVTMNDFDYLKLLGKGTFGKVILVREKATGRYYAM : 180
Akt-3 : DTPEEREEWTEAIQAVADRLQRQE--EERMNCSPTSQIDNIGEEEMDASTTHHK-RKTMNDFDYLKLLGKGTFGKVILVREKASGKYYAM : 176
Akt-1 : KILKKEVIVAKDEVAHTVTESRVLQNSRHPFLTALKYSFQTHDRLCFVMEYANGGELFFHLSRERVFSEDRARFYGAEIVSALDYLHSEK : 268
Akt-2 : KILRKEVIIAKDEVAHTVTESRVLQNTRHPFLTALKYAFQTHDRLCFVMEYANGGELFFHLSRERVFTEERARFYGAEIVSALEYLHS-R : 269
Akt-3 : KILKKEVIIAKDEVAHTVTESRVLKNTRHPFLTSLKYSFQTKDRLCFVMEYVNGGELFFHLSRERVFSEDRTRFYGAEIVSALDYLHS-G : 265
Akt-1 : NVVYRDLKLENLMLDKDGHIKITDFGLCKEGIKDGATMKTFCGTPEYLAPEVLEDNDYGRAVDWWGLGVVMYEMMCGRLPFYNQDHEKLF : 358
Akt-2 : DVVYRDIKLENLMLDKDGHIKITDFGLCKEGISDGATMKTFCGTPEYLAPEVLEDNDYGRAVDWWGLGVVMYEMMCGRLPFYNQDHERLF : 359
Akt-3 : KIVYRDIKLENLMLDKDGHIKITDFGLCKEGITDAATMKTFCGTPEYLAPEVLEDNDYGRAVDWWGLGVVMYEMMCGRLPFYNQDHEKLF : 355
Akt-1 : ELILMEEIRFPRTLGPEAKSLLSGLLKKDPKQRLGGGSEDAKEIMQHRFFAGIVWCHVYEKKLSPPFKPQVTSETDTRYFDEEFTAQMIT : 448
Akt-2 : ELILMEEIRFPRTLSPEAKSLLAGLLKKDPKQRLGGGPSDAKEVMEHRFFLSINWQDVVQKKLLPPFKPQVTSEVDTRYFDDEFTAQSIT : 449
Akt-3 : ELILMEDIKFPRTLSSDAKSLLSGLLIKDPNKRLGGGPDDAKEIMRHSFFSGVNWQDVYDKKLVPPFKPQVTSETDTRYFDEEFTAQTIT : 445
Akt-1 : ITPPDQDDS--MECVDSERRPHFPQFSYSASGTA : 480
Akt-2 : ITPPDRYDS--LGLLELDQRTHFPQFSYSASIRE : 481
Akt-3 : ITPPEKYLEDGMDMMLNERRPHFPQFSYSASGRE : 479

Fig 2

A


Relative H2B phosphorylation
1.0
0.5
0.0
kD
1 2 3 4 5
113-
82-
49-
35-
0
10
20
30
40
50
Time (min)
T305D, S472D
T305D
S472D
W.T.

B


Vector
Akt-3
IGF - + - +
Kinase Assay
Anti-HA Blot
1 2 3 4

Fig 3


H2B Phosphorylation (%)
100
50
0
C
-8
-7
-6
-5
-4
log {[staurosporine] (M)}


H2B Phosphorylation (%)
100
50
0
C
-8
-7
-6
-5
-4
log {[Ro 31-8220] (M)}

Figure 4.



Fig 5


kb
Heart
Brain
Placenta
Lung
Liver
Skeletal Muscle
Kidney
Pancreas
9.5
7.5
4.4
2.4

Figure 6A



Figure 6B



Figure 6C